Ginny L Bumgardner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3954527/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation. New England Journal of Medicine, 1998, 338, 161-165.	13.9	884
2	Reproduction and Transplantation: Report on the AST Consensus Conference on Reproductive Issues and Transplantation. American Journal of Transplantation, 2005, 5, 1592-1599.	2.6	410
3	Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney International, 1998, 53, 767-772.	2.6	282
4	The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clinical Transplantation, 2003, 17, 200-205.	0.8	185
5	IMPACT OF ACUTE REJECTION AND EARLY ALLOGRAFT FUNCTION ON RENAL ALLOGRAFT SURVIVAL. Transplantation, 1997, 63, 1611-1615.	0.5	132
6	Racial differences in renal allograft survival: The role of systemic hypertension. Kidney International, 1995, 47, 1136-1141.	2.6	108
7	SINGLE-CENTER LONG-TERM RESULTS OF RENAL TRANSPLANTATION FOR IgA NEPHROPATHY1. Transplantation, 1998, 65, 1053-1060.	0.5	96
8	RESULTS OF 3-YEAR PHASE III CLINICAL TRIALS WITH DACLIZUMAB PROPHYLAXIS FOR PREVENTION OF ACUTE REJECTION AFTER RENAL TRANSPLANTATION1. Transplantation, 2001, 72, 839-845.	0.5	95
9	FACTORS RELATED TO THE DONOR ORGAN ARE MAJOR DETERMINANTS OF RENAL ALLOGRAFT FUNCTION AND SURVIVAL. Transplantation, 1996, 62, 1571-1576.	0.5	84
10	THE HIGH PREVALENCE OF SEVERE EARLY POSTTRANSPLANT RENAL ALLOGRAFT PATHOLOGY IN HEPATITIS C POSITIVE RECIPIENTS. Transplantation, 1996, 62, 1054-1059.	0.5	74
11	A FUNCTIONAL MODEL OF HEPATOCYTE TRANSPLANTATION FOR IN VIVO IMMUNOLOGIC STUDIES1,2. Transplantation, 1998, 65, 53-61.	0.5	70
12	Urological Aspects of Renal Transplantation. Journal of Urology, 1990, 143, 1087-1092.	0.2	68
13	Equivalent Pharmacokinetics of Mycophenolate Mofetil in African-American and Caucasian Male and Female Stable Renal Allograft Recipients. American Journal of Transplantation, 2003, 3, 1581-1586.	2.6	66
14	OBESITY AS A RISK FACTOR AFTER COMBINED PANCREAS/KIDNEY TRANSPLANTATION1. Transplantation, 1995, 60, 1426-1430.	0.5	60
15	IN VIVO IMMUNOGENICITY OF PURIFIED ALLOGENEIC HEPATOCYTES IN A MURINE HEPATOCYTE TRANSPLANT MODEL1,2. Transplantation, 1998, 65, 47-52.	0.5	57
16	SINGLE-CENTER 1–15-YEAR RESULTS OF RENAL TRANSPLANTATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Transplantation, 1988, 46, 703-709.	0.5	56
17	Unusual patterns of alloimmunity evoked by allogeneic liver parenchymal cells. Immunological Reviews, 2000, 174, 260-279.	2.8	55
18	Prospects for hepatocyte transplantation. Hepatology, 1988, 8, 1158-1161.	3.6	50

2

#	Article	IF	CITATIONS
19	IMPACT OF SERUM LIPIDS ON LONG-TERM GRAFT AND PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION1. Transplantation, 1995, 60, 1418-1421.	0.5	50
20	COMPARISON OF IN VIVO AND IN VITRO IMMUNE RESPONSE TO PURIFIED HEPATOCYTES. Transplantation, 1990, 49, 429-435.	0.5	49
21	Prophylactic Cholecystectomy Is Not Indicated following Renal Transplantation 11Supported by a grant from the Samuel J. Roessler Research Foundation of the School of Medicine of the Ohio State University American Journal of Surgery, 1998, 175, 317-319.	0.9	48
22	Relationships between arterial hypertension and renal allograft survival in African-American patients. American Journal of Kidney Diseases, 1997, 29, 419-427.	2.1	47
23	REJECTION RESPONSES TO ALLOGENEIC HEPATOCYTES BY RECONSTITUTED SCID MICE, CD4 KO, AND CD8 KO MICE1,2. Transplantation, 2000, 70, 1771-1780.	0.5	46
24	Monitoring Infection with Epstein–Barr Virus among Seromismatch Adult Renal Transplant Recipients. American Journal of Transplantation, 2011, 11, 1058-1063.	2.6	46
25	PATTERNS OF IMMUNE RESPONSES EVOKED BY ALLOGENEIC HEPATOCYTES. Transplantation, 1999, 68, 555-562.	0.5	46
26	Pancreas after Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2002, 13, 1109-1118.	3.0	43
27	The laparoscopic management of post-transplant lymphocele. Surgical Endoscopy and Other Interventional Techniques, 1997, 11, 245-248.	1.3	42
28	Obesity, transplantation, and bariatric surgery: An evolving solution for a growing epidemic. American Journal of Transplantation, 2020, 20, 2143-2155.	2.6	39
29	Different Costimulation Signals Used by CD4+ and CD8+ Cells That Independently Initiate Rejection of Allogenic Hepatocytes in Mice. Hepatology, 2000, 32, 1018-1028.	3.6	38
30	INCREASED INCIDENCE OF GASTROINTESTINAL SURGICAL COMPLICATIONS IN RENAL TRANSPLANT RECIPIENTS WITH POLYCYSTIC KIDNEY DISEASE1. Transplantation, 1999, 67, 262-266.	0.5	38
31	The optimal number of donor biopsy sites to evaluate liver histology for transplantation. Liver Transplantation, 2002, 8, 1044-1050.	1.3	37
32	Academic Careers and Lifestyle Characteristics of 171 Transplant Surgeons in the ASTSa~ American Journal of Transplantation, 2011, 11, 261-271.	2.6	34
33	PATHOLOGIC CLASSIFICATION OF CHRONIC ALLOGRAFT NEPHROPATHY: PATHOGENIC AND PROGNOSTIC IMPLICATIONS1. Transplantation, 1999, 67, 690-696.	0.5	34
34	COSTIMULATION PATHWAYS IN HOST IMMUNE RESPONSES TO ALLOGENEIC HEPATOCYTES1,2. Transplantation, 1998, 66, 1841-1845.	0.5	33
35	OBESE LIVING KIDNEY DONORS: SHORT-TERM RESULTS AND POSSIBLE IMPLICATIONS1. Transplantation, 1999, 68, 1491-1496.	0.5	33
36	Targeting LFAâ€l Synergizes with CD40/CD40L Blockade for Suppression of Both CD4â€Dependent and CD8â€Dependent Rejection. American Journal of Transplantation, 2003, 3, 1251-1258.	2.6	31

#	Article	IF	CITATIONS
37	Targeting LFA-1 and CD154 Suppresses the In Vivo Activation and Development of Cytolytic (CD4-Independent) CD8+T Cells. Journal of Immunology, 2005, 175, 7855-7866.	0.4	31
38	AFFERENT AND EFFERENT PATHWAYS IN T CELL RESPONSES TO MHC CLASS I+, II-HEPATOCYTES. Transplantation, 1989, 47, 163-170.	0.5	30
39	Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clinical Transplantation, 2003, 17, 511-517.	0.8	30
40	Transplantation and pregnancy. Transplantation Reviews, 1992, 6, 139-162.	1.2	28
41	Steroid-Free Maintenance Immunosuppression With Rapamune and Low-Dose Neoral in Pancreas Transplant Recipients. Transplantation, 2007, 84, 1131-1137.	0.5	25
42	DACLIZUMAB (HUMANIZED ANTI-IL2R?? MAB) PROPHYLAXIS FOR PREVENTION OF ACUTE REJECTION IN RENAL TRANSPLANT RECIPIENTS WITH DELAYED GRAFT FUNCTION1,2. Transplantation, 2001, 72, 642-647.	0.5	23
43	Critical Role of Effector Macrophages in Mediating CD4-Dependent Alloimmune Injury of Transplanted Liver Parenchymal Cells. Journal of Immunology, 2008, 181, 1224-1231.	0.4	23
44	Alloprimed CD8+ T Cells Regulate Alloantibody and Eliminate Alloprimed B Cells Through Perforin- and FasL-Dependent Mechanisms. American Journal of Transplantation, 2014, 14, 295-304.	2.6	22
45	A randomized prospective trial of OKT3 induction in the current immunosuppression era. Clinical Transplantation, 2001, 15, 410-414.	0.8	21
46	Genetic Modification of Hepatocytes towards Hepatocyte Transplantation and Liver Tissue Engineering. Cell Transplantation, 2006, 15, 1-12.	1.2	21
47	CLINICAL AND ECONOMIC IMPACT OF FLOW CYTOMETRY CROSSMATCHING IN PRIMARY CADAVERIC KIDNEY AND SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANT RECIPIENTS1. Transplantation, 1997, 63, 1639-1645.	0.5	21
48	Evidence for Tissue-Directed Immune Responses: Analysis of CD4- and CD8-Dependent Alloimmunity. Transplantation, 2004, 78, 1125-1133.	0.5	20
49	Activation and Maturation of Alloreactive CD4-Independent, CD8+Cytolytic T Cells. American Journal of Transplantation, 2006, 6, 2268-2281.	2.6	20
50	Disparate Primary and Secondary Allospecific CD8+ T Cell Cytolytic Effector Function in the Presence or Absence of Host CD4+ T Cells. Journal of Immunology, 2007, 179, 80-88.	0.4	20
51	Hand-assisted laparoscopic versus open nephrectomies in living donors. Canadian Journal of Surgery, 2005, 48, 123-30.	0.5	20
52	Pulmonary Rhizopus infection in a diabetic renal transplant recipient. Clinical Transplantation, 2000, 14, 8-10.	0.8	19
53	CD4+ T-Cell???Dependent Immune Damage of Liver Parenchymal Cells Is Mediated by Alloantibody. Transplantation, 2005, 80, 514-521.	0.5	18
54	CD8+ T Cells Negatively Regulate IL-4–Dependent, IgG1-Dominant Posttransplant Alloantibody Production. Journal of Immunology, 2010, 185, 7285-7292.	0.4	18

#	Article	IF	CITATIONS
55	Modulation of MHC class I antigen decreases pancreatic islet immunogenicity. Journal of Surgical Research, 1989, 46, 317-321.	0.8	17
56	Effect of tumor necrosis factor ? and intercellular adhesion molecule-1 expression on immunogenicity of murine liver cells in mice. Hepatology, 1998, 28, 466-474.	3.6	17
57	Twenty years of renal transplantation at Ohio State University: the results of five eras of immunosuppression. American Journal of Surgery, 2003, 186, 306-311.	0.9	17
58	Antibody-suppressor CD8+ T Cells Require CXCR5. Transplantation, 2019, 103, 1809-1820.	0.5	17
59	CELL SUBSETS RESPONDING TO PURIFIED HEPATOCYTES AND EVIDENCE OF INDIRECT RECOGNITION OF HEPATOCYTE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I ANTIGEN. Transplantation, 1992, 53, 857-862.	0.5	16
60	Transplantation and Cytokines. Seminars in Liver Disease, 1999, 19, 189-204.	1.8	15
61	OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient. Transplantation, 2002, 73, 1957-1959.	0.5	15
62	Cytotoxic Effector Function of CD4-Independent, CD8+ T Cells Is Mediated by TNF-α/TNFR. Transplantation, 2012, 94, 1103-1110.	0.5	15
63	MHC-identical heart and hepatocyte allografts evoke opposite immune responses within the same host Transplantation, 2002, 74, 855-864.	0.5	14
64	Critical Role for CD8+ T Cells in Allograft Acceptance Induced by DST and CD40/CD154 Costimulatory Blockade. American Journal of Transplantation, 2004, 4, 1061-1070.	2.6	14
65	Alloreactive (CD4-Independent) CD8+ T Cells Jeopardize Long-Term Survival of Intrahepatic Islet Allografts. American Journal of Transplantation, 2008, 8, 1113-1128.	2.6	14
66	mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells. Transplantation, 2016, 100, 1898-1906.	0.5	14
67	Efficacy of anti-intercellular adhesion molecule-1 immunotherapy on immune responses to allogeneic hepatocytes in mice. Hepatology, 1998, 28, 1005-1012.	3.6	12
68	Simultaneous Pancreas/Kidney Transplantation: Comparison of Mycophenolate Mofetil Versus Azathioprine. Transplantation Proceedings, 1998, 30, 512.	0.3	11
69	Magnetic Resonance Cholangiography With Mangafodipir Trisodium (Teslascan) to Evaluate Bile Duct Leaks After T-Tube Removal in Liver Transplantation. Journal of Computer Assisted Tomography, 2004, 28, 613-616.	0.5	11
70	Recipient Immune Repertoire and Engraftment Site Influence the Immune Pathway Effecting Acute Hepatocellular Allograft Rejection. Cell Transplantation, 2008, 17, 829-844.	1.2	11
71	Magnetic resonance angiography for preoperative evaluation of potential kidney donors1. Journal of Surgical Research, 2004, 120, 195-200.	0.8	10
72	Inverse Association Between the Quantity of Human Peripheral Blood CXCR5+IFN-Ĵ³+CD8+ T Cells With De Novo DSA Production in the First Year After Kidney Transplant. Transplantation, 2020, 104, 2424-2434.	0.5	10

#	Article	IF	CITATIONS
73	Outcome of 300 Consecutive Pancreas–Kidney Transplants. Transplantation Proceedings, 1998, 30, 291.	0.3	9
74	Critical Role of NKT Cells in Posttransplant Alloantibody Production. American Journal of Transplantation, 2014, 14, 2491-2499.	2.6	9
75	Genetic modification of hepatocytes towards hepatocyte transplantation and liver tissue engineering. Cell Transplantation, 2006, 15, 1-12.	1.2	9
76	In vivo immune response to allogeneic hepatocytes. Transplantation Proceedings, 1997, 29, 2059-2060.	0.3	8
77	Early immunosuppression treatment correlates with later <i>de novo</i> donorâ€specific antibody development after kidney and pancreas transplantation. Clinical Transplantation, 2015, 29, 1119-1127.	0.8	7
78	Unique CD8+ T Cell–Mediated Immune Responses Primed in the Liver. Transplantation, 2016, 100, 1907-1915.	0.5	7
79	Critical Role of Macrophage Fcl ³ R Signaling and Reactive Oxygen Species in Alloantibody-Mediated Hepatocyte Rejection. Journal of Immunology, 2018, 201, 3731-3740.	0.4	7
80	CXCR5+CD8+ T Cells: A Review of Their Antibody Regulatory Functions and Clinical Correlations. Journal of Immunology, 2021, 206, 2775-2783.	0.4	7
81	Role of macrophages in the immune response to hepatocytes. Journal of Surgical Research, 1990, 48, 568-572.	0.8	6
82	Hepatocyte immunology and transplantation: current status and future potential. Current Opinion in Organ Transplantation, 2005, 10, 67-76.	0.8	6
83	"Early―and "Late―Hospital readmissions in the first year after kidney transplant at a single center. Clinical Transplantation, 2020, 34, e13822.	0.8	6
84	Facilitating Success of the Early Stage Surgeon Scientist Trainee. Annals of Surgery, 2022, 275, e334-e344.	2.1	6
85	FUNCTION AND SURVIVAL OF RENAL ALLOGRAFTS FROM THE SAME DONOR TRANSPLANTED INTO KIDNEY-ONLY OR KIDNEY-PANCREAS RECIPIENTS1. Transplantation, 1998, 65, 93-99.	0.5	6
86	Invariant NKT Cells Promote the Development of Highly Cytotoxic Multipotent CXCR3+CCR4+CD8+ T Cells That Mediate Rapid Hepatocyte Allograft Rejection. Journal of Immunology, 2021, 207, 3107-3121.	0.4	6
87	Antibody-suppressor CXCR5+CD8+ T cellular therapy ameliorates antibody-mediated rejection following kidney transplant in CCR5 KO mice. American Journal of Transplantation, 2022, 22, 1550-1563.	2.6	6
88	Inhibition of Recall Responses through Complementary Therapies Targeting CD8 ⁺ T-Cell- and Alloantibody-Dependent Allocytotoxicity in Sensitized Transplant Recipients. Cell Transplantation, 2013, 22, 1157-1169.	1.2	5
89	CLINICAL IMPLICATIONS OF THE DIAGNOSIS OF RENAL ALLOGRAFT INFARCTION BY PERCUTANEOUS BIOPSY1. Transplantation, 1998, 66, 467-471.	0.5	5
90	BASILIXIMAB VS OKT3 IN PRIMARY SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANT RECIPIENTS Transplantation, 2000, 69, S407.	0.5	4

#	Article	IF	CITATIONS
91	Reproduction and pregnancy in transplant recipients: current practices. Progress in Transplantation, 2006, 16, 127-32.	0.4	4
92	Newer cephalosporins: Lessons to be learned from clinical trials in intraabdominal infections. American Journal of Surgery, 1988, 155, 5-10.	0.9	3
93	Hepatocyte Transplantation and Humoral Alloimmunity. American Journal of Transplantation, 2016, 16, 1940.	2.6	3
94	The impact of donor and recipient diabetes on renal transplant outcomes. Clinical Transplantation, 2020, 34, e14115.	0.8	3
95	Pretransplant sensitization with major histocompatibility complex class I+ class IIâ^' hepatocytes leads to accelerated skin graft rejection. Journal of Surgical Research, 1992, 53, 182-187.	0.8	2
96	Simultaneous Pancreas-Kidney Transplantation: Overview of the Ohio State Experience. Yonsei Medical Journal, 2004, 45, 1095.	0.9	2
97	Pulsatile perfusion: a preservation strategy to optimize the use and function of transplanted kidneys. Current Opinion in Organ Transplantation, 2007, 12, 345-350.	0.8	2
98	Liver immunology: A new section for the journal. Liver Transplantation, 2017, 23, 1371-1371.	1.3	0
99	Ginny L. Bumgardner, MD, PhD. Transplantation, 2017, 101, 2650-2652.	0.5	0
100	Thoracic transplantation during the COVIDâ€19 pandemic. Clinical Transplantation, 2021, , e14575.	0.8	0